[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Loxapine.]
[N05AL01, sulpiride, Loxapine may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Loxapine is combined with Sulthiame.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Loxapine.]
[L01CB02, teniposide, Loxapine may increase the neurotoxic activities of Teniposide.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Loxapine.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Loxapine.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[N04BC07, apomorphine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Loxapine.]
[L04AX02, thalidomide, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Loxapine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Loxapine is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Loxapine is combined with Thiothixene.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Loxapine is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Loxapine is combined with Tilidine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Loxapine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loxapine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Loxapine.]
[S01BA05, triamcinolone, The therapeutic efficacy of Triamcinolone can be decreased when used in combination with Loxapine.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Loxapine is combined with Triazolam.]
[A03AB12, mepenzolate, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Loxapine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Loxapine.]
[A03AA05, trimebutine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Loxapine.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Loxapine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Loxapine is combined with Triprolidine.]
[A03BB01, butylscopolamine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Loxapine.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Loxapine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Loxapine is combined with Tubocurarine.]
[R03DX07, roflumilast, The therapeutic efficacy of Roflumilast can be decreased when used in combination with Loxapine.]
[A10BH05, linagliptin, The serum concentration of Linagliptin can be increased when it is combined with Loxapine.]
[J05AP02, telaprevir, The serum concentration of Telaprevir can be increased when it is combined with Loxapine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Loxapine is combined with Ezogabine.]
[B01AF01, rivaroxaban, The serum concentration of Rivaroxaban can be increased when it is combined with Loxapine.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Loxapine.]
[B01AC24, ticagrelor, The serum concentration of Ticagrelor can be increased when it is combined with Loxapine.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Loxapine.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Loxapine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Loxapine is combined with Warfarin.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Loxapine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Vemurafenib can be increased when it is combined with Loxapine.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Loxapine.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Loxapine.]
[R03DC01, zafirlukast, The therapeutic efficacy of Zafirlukast can be decreased when used in combination with Loxapine.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Loxapine is combined with Ziprasidone.]
[G04BD07, tolterodine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Loxapine is combined with Atracurium.]
[S01FA01, atropine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Loxapine.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Loxapine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Loxapine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Loxapine.]
[G04BD12, mirabegron, The serum concentration of Mirabegron can be increased when it is combined with Loxapine.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Loxapine.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Loxapine.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Loxapine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Barbital.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Loxapine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[N04BD02, rasagiline, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Loxapine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Loxapine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Loxapine is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Loxapine.]
[R06AC06, thonzylamine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Loxapine is combined with Diethyl ether.]
[G04BE03, sildenafil, The serum concentration of Sildenafil can be increased when it is combined with Loxapine.]
[B01AF02, apixaban, The serum concentration of Apixaban can be increased when it is combined with Loxapine.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Loxapine.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Loxapine is combined with Benperidol.]
[A10BK02, canagliflozin, The serum concentration of Canagliflozin can be increased when it is combined with Loxapine.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Loxapine.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Benzocaine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Loxapine.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Loxapine.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Loxapine is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be increased when it is combined with Loxapine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Loxapine is combined with Benzyl alcohol.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Loxapine.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Loxapine is combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Loxapine.]
[C02KX05, riociguat, The serum concentration of Riociguat can be increased when it is combined with Loxapine.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Loxapine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Loxapine is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Simeprevir can be increased when it is combined with Loxapine.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Loxapine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Loxapine is combined with Vigabatrin.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Loxapine is combined with Tasimelteon.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Loxapine.]
[A03BA03, hyoscyamine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Loxapine is combined with Acenocoumarol.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Loxapine.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Loxapine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Loxapine is combined with Alfaxalone.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Loxapine.]
[D11AA01, glycopyrronium, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Acepromazine.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Loxapine.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Loxapine.]
[L01EX09, nintedanib, The serum concentration of Nintedanib can be increased when it is combined with Loxapine.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Loxapine.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Loxapine is combined with Dicoumarol.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Loxapine.]
[N06AX11, mirtazapine, Loxapine may increase the serotonergic activities of Mirtazapine.]
[L01EX08, lenvatinib, The serum concentration of Lenvatinib can be increased when it is combined with Loxapine.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Loxapine.]
[A03AA09, difemerine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Loxapine is combined with Tioclomarol.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Loxapine is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Loxapine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Loxapine is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Acetophenazine.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Loxapine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Loxapine.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Loxapine.]
[B01AC27, selexipag, The serum concentration of Selexipag can be increased when it is combined with Loxapine.]
[J05AP10, elbasvir, The serum concentration of Elbasvir can be increased when it is combined with Loxapine.]
[J05AP11, grazoprevir, The serum concentration of Grazoprevir can be increased when it is combined with Loxapine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Aprobarbital.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Loxapine is combined with Brivaracetam.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Loxapine.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Bromazepam.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Loxapine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Loxapine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loxapine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Loxapine is combined with Amineptine.]
[N05AX17, pimavanserin, Loxapine may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Loxapine is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Loxapine.]
[N07BC01, buprenorphine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Loxapine is combined with Buspirone.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Loxapine is combined with Butorphanol.]
[S01GX07, azelastine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Loxapine.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Loxapine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Loxapine is combined with Beclamide.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Loxapine.]
[J05AE09, tipranavir, The serum concentration of Tipranavir can be increased when it is combined with Loxapine.]
[N04BD03, safinamide, The therapeutic efficacy of Safinamide can be decreased when used in combination with Loxapine.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Loxapine.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loxapine.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Loxapine.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Loxapine.]
[A02BX12, bismuth subnitrate, Loxapine may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Loxapine.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Loxapine is combined with Efavirenz.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Loxapine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Loxapine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Loxapine is combined with Brotizolam.]
[R03BA02, budesonide, The therapeutic efficacy of Budesonide can be decreased when used in combination with Loxapine.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Loxapine.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Loxapine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Loxapine may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BK04, ertugliflozin, The serum concentration of Ertugliflozin can be increased when it is combined with Loxapine.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Loxapine is combined with Vinylbital.]
[N03AF01, carbamazepine, The serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Loxapine.]
[A03AA03, camylofine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Carbinoxamine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Loxapine.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Loxapine.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Loxapine.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Loxapine.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Loxapine is combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Loxapine.]
[L01EM04, duvelisib, The serum concentration of Duvelisib can be increased when it is combined with Loxapine.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Loxapine.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Loxapine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Loxapine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Loxapine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Loxapine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Loxapine.]
[R03BB08, revefenacin, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX12, larotrectinib, The serum concentration of Larotrectinib can be increased when it is combined with Loxapine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Loxapine can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Glasdegib can be increased when it is combined with Loxapine.]
[A06AX05, prucalopride, The serum concentration of Prucalopride can be increased when it is combined with Loxapine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Loxapine is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Loxapine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Loxapine is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Loxapine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Loxapine is combined with Cloxazolam.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be increased when it is combined with Loxapine.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Cyamemazine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Loxapine.]
[L01EJ02, fedratinib, The serum concentration of Fedratinib can be increased when it is combined with Loxapine.]
[J01XX12, lefamulin, Loxapine may decrease the excretion rate of Lefamulin which could result in a higher serum level.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Loxapine.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Loxapine is combined with Yohimbine.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Loxapine.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Loxapine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Loxapine.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Loxapine.]
[L01FX13, enfortumab vedotin, The serum concentration of Enfortumab vedotin can be increased when it is combined with Loxapine.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loxapine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Loxapine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Loxapine is combined with Lemborexant.]
[L01XX72, tazemetostat, The serum concentration of Tazemetostat can be increased when it is combined with Loxapine.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Loxapine.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Loxapine.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Loxapine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Loxapine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Loxapine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Loxapine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Loxapine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Loxapine.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Loxapine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Loxapine is combined with Chlordiazepoxide.]
[L01EH03, tucatinib, The serum concentration of Tucatinib can be increased when it is combined with Loxapine.]
[A03AA08, dihexyverine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Loxapine.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Loxapine.]
[G04BD09, trospium, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX19, ripretinib, The serum concentration of Ripretinib can be increased when it is combined with Loxapine.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Loxapine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Loxapine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.]
[J05AX29, fostemsavir, The serum concentration of Fostemsavir can be increased when it is combined with Loxapine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Loxapine is combined with Remimazolam.]
[L01FX15, belantamab mafodotin, The serum concentration of Belantamab mafodotin can be increased when it is combined with Loxapine.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Loxapine is combined with Oliceridine.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Loxapine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Loxapine.]
[N05AA01, chlorpromazine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Loxapine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Loxapine is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Loxapine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl loflazepate.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Loxapine.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Loxapine.]
[L01FX21, naxitamab, Loxapine may increase the neurotoxic activities of Naxitamab.]
[L04AD03, voclosporin, The serum concentration of Voclosporin can be increased when it is combined with Loxapine.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Loxapine.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Loxapine.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Loxapine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Loxapine is combined with Felbamate.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Loxapine.]
[R03BA03, flunisolide, The therapeutic efficacy of Flunisolide can be decreased when used in combination with Loxapine.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Loxapine.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Loxapine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Loxapine is combined with Trichloroethylene.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Loxapine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Loxapine is combined with Citalopram.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Loxapine.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Loxapine.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Loxapine.]
[J01FF01, clindamycin, Loxapine may increase the neurotoxic activities of Clindamycin.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Loxapine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Loxapine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Levobupivacaine.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Loxapine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Clomipramine is combined with Loxapine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Loxapine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Loxapine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Loxapine is combined with Granisetron.]
[N05AH02, clozapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Loxapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Halazepam.]
[S02DA02, cocaine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Loxapine may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Loxapine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Loxapine is combined with Hexafluronium.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Loxapine.]
[A03AB10, hexocyclium, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Loxapine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Loxapine is combined with Tropisetron.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Loxapine.]
[R03BA08, ciclesonide, The therapeutic efficacy of Ciclesonide can be decreased when used in combination with Loxapine.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Loxapine is combined with Desloratadine.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Loxapine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Loxapine is combined with Ketazolam.]
[J02AC04, posaconazole, The serum concentration of Posaconazole can be increased when it is combined with Loxapine.]
[N03AX09, lamotrigine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Loxapine can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Lormetazepam.]
[A03AA04, mebeverine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Medifoxamine.]
[R06AD07, mequitazine, Loxapine may increase the arrhythmogenic activities of Mequitazine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Loxapine.]
[R03CB02, methoxyphenamine, Loxapine may decrease the stimulatory activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Loxapine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Loxapine is combined with Melperone.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Loxapine.]
[L01AA01, cyclophosphamide, Loxapine may increase the neurotoxic activities of Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Loxapine is combined with Minaprine.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Loxapine.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Loxapine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Loxapine.]
[R06AX02, cyproheptadine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[R03DX05, omalizumab, The therapeutic efficacy of Omalizumab can be decreased when used in combination with Loxapine.]
[G04BE09, vardenafil, The serum concentration of Vardenafil can be increased when it is combined with Loxapine.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Loxapine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Loxapine is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Loxapine is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Loxapine is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Loxapine is combined with Tiagabine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Loxapine is combined with Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Loxapine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Escitalopram.]
[G04BD08, solifenacin, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxcarbazepine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxiracetam.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Loxapine.]
[G04BD04, oxybutynin, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, Loxapine may decrease the stimulatory activities of Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Loxapine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Loxapine is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Loxapine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Loxapine is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Loxapine is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Loxapine is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Loxapine is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Loxapine is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Cinchocaine.]
[A03AA07, dicyclomine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Loxapine may increase the neurotoxic activities of Didanosine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Loxapine is combined with Pipamperone.]
[A03AB14, pipenzolate, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Loxapine.]
[A08AA03, diethylpropion, Loxapine may decrease the stimulatory activities of Diethylpropion.]
[A03AB11, poldine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Loxapine.]
[C01AA05, digoxin, Loxapine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Loxapine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Loxapine is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Loxapine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Loxapine is combined with Pridinol.]
[R06AB03, dimethindene, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Loxapine.]
[R06AA02, diphenhydramine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Loxapine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Loxapine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Loxapine is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Loxapine is combined with Cisapride.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Loxapine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride.]
[C01BA03, disopyramide, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The serum concentration of Rifamycin can be increased when it is combined with Loxapine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Loxapine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Loxapine is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Loxapine is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Loxapine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Loxapine.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Loxapine.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Loxapine.]
[C02KX02, ambrisentan, The serum concentration of Ambrisentan can be increased when it is combined with Loxapine.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Loxapine.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Loxapine.]
[N06AA16, dothiepin, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Loxapine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Loxapine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Loxapine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Loxapine is combined with Sibutramine.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Loxapine.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Loxapine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Loxapine.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Loxapine.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Loxapine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Loxapine is combined with Thiopropazate.]
[G04BD01, emepronium, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Loxapine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Loxapine is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Loxapine is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Loxapine.]
[L02BA02, toremifene, The serum concentration of Toremifene can be increased when it is combined with Loxapine.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loxapine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Loxapine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Loxapine is combined with Triclofos.]
[A03AB08, tridihexethyl, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Loxapine is combined with Trimethobenzamide.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Loxapine.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Loxapine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Loxapine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Loxapine is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Loxapine is combined with Veralipride.]
[L01CA04, vinorelbine, Vinorelbine may increase the neurotoxic activities of Loxapine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Loxapine is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Venlafaxine.]
[N05CF02, zolpidem, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Loxapine is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Loxapine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Loxapine is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Loxapine is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Loxapine is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Loxapine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Loxapine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Loxapine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Loxapine is combined with Estazolam.]
[C01CA15, gepefrine, Loxapine may decrease the stimulatory activities of Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loxapine.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Loxapine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Loxapine is combined with Ethotoin.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Loxapine is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Loxapine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Loxapine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Loxapine is combined with Sertindole.]
[R06AX12, terfenadine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Loxapine is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Fluvoxamine.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be increased when it is combined with Loxapine.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Loxapine.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Loxapine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Loxapine.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Loxapine.]
[G04BD02, flavoxate, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Loxapine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Loxapine is combined with Melitracen.]
[V03AZ01, ethanol, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Fluoxetine.]
[N05AF01, flupenthixol, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Flurazepam.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Loxapine is combined with Fluspirilene.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Loxapine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Loxapine is combined with Furazolidone.]
[J05AE10, darunavir, The serum concentration of Darunavir can be increased when it is combined with Loxapine.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Loxapine is combined with Eszopiclone.]
[N05AL05, amisulpride, Loxapine may increase the antipsychotic activities of Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Gallamine.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Loxapine is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Loxapine is combined with Bifemelane.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Loxapine.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be decreased when used in combination with Loxapine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Loxapine is combined with Alfentanil.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Loxapine is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Loxapine is combined with Glutethimide.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Loxapine is combined with Fluindione.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Loxapine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Loxapine is combined with Halothane.]
[N05AH04, quetiapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Loxapine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Allobarbital.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Hexobarbital.]
[R05DA03, hydrocodone, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Loxapine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[B05CB02, sodium citrate, Loxapine may increase the neurotoxic activities of Sodium citrate.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Loxapine.]
[L01CD01, paclitaxel, Loxapine may increase the neurotoxic activities of Paclitaxel.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Loxapine is combined with Tizanidine.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Loxapine.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Loxapine is combined with Milnacipran.]
[A03AA30, piperidolate, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Sitagliptin can be increased when it is combined with Loxapine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Loxapine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Loxapine is combined with Ramelteon.]
[R06AE01, buclizine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Loxapine is combined with Alprenolol.]
[J05AF04, stavudine, Loxapine may increase the neurotoxic activities of Stavudine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Loxapine is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Loxapine is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Loxapine.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Loxapine is combined with Isoflurane.]
[N04BX02, entacapone, The therapeutic efficacy of Entacapone can be decreased when used in combination with Loxapine.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Loxapine.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Loxapine is combined with Ketanserin.]
[N05AH03, olanzapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[N04BC09, rotigotine, Loxapine may increase the sedative activities of Rotigotine.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Loxapine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Loxapine is combined with Lacosamide.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Loxapine.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Loxapine.]
[J01FF02, lincomycin, Loxapine may increase the neurotoxic activities of Lincomycin.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be decreased when used in combination with Loxapine.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Loxapine is combined with Lofepramine.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Loxapine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Lorazepam.]
[N07XX04, sodium oxybate, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Loxapine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Loxapine can be increased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Loxapine.]
[N06AA21, maprotiline, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Loxapine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Loxapine is combined with Meclizine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Medazepam.]
[C01AA08, medigoxin, Loxapine may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[P01BC02, mefloquine, The serum concentration of Mefloquine can be increased when it is combined with Loxapine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Loxapine is combined with Melatonin.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Loxapine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Loxapine.]
[C01CA11, mephentermine, Loxapine may decrease the stimulatory activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Loxapine is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Loxapine is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Loxapine is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Loxapine.]
[N06BA03, methamphetamine, Loxapine may decrease the stimulatory activities of Metamfetamine.]
[A03AB07, methantheline, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Loxapine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Loxapine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Metharbital.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Loxapine is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Loxapine is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Loxapine is combined with Methohexital.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Loxapine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Loxapine is combined with Methoxyflurane.]
[V04CG05, methylene blue, Loxapine may increase the serotonergic activities of Methylene blue.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Loxapine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Loxapine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Loxapine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Loxapine.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[N06BA12, lisdexamfetamine, Loxapine may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Loxapine is combined with Molindone.]
[N06AA09, amitriptyline, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Loxapine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Loxapine.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Loxapine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Loxapine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Amobarbital.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Loxapine.]
[N06AA17, amoxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Loxapine is combined with Fosphenytoin.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Loxapine.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Loxapine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Loxapine is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Naltrexone.]
[N06BA01, amphetamine, Loxapine may decrease the stimulatory activities of Amphetamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Loxapine is combined with Duloxetine.]
[N04BX01, tolcapone, The therapeutic efficacy of Tolcapone can be decreased when used in combination with Loxapine.]
[S03AA01, neomycin, Loxapine may increase the neurotoxic activities of Neomycin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Loxapine is combined with Remifentanil.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Loxapine is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Loxapine is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Loxapine is combined with Nialamide.]
[C08CA04, nicardipine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Nitrazepam.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Loxapine is combined with Zaleplon.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Loxapine.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Loxapine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Loxapine is combined with Nomifensine.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Loxapine.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Loxapine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Loxapine is combined with Opium.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Loxapine.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Loxapine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxazepam.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxypertine.]
[A03AB03, oxyphenonium, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[M03AC01, pancuronium, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Loxapine is combined with Pargyline.]
[G04BD11, fesoterodine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Loxapine is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Loxapine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Loxapine.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Loxapine.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Loxapine is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Loxapine.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Loxapine is combined with Phenindione.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Loxapine is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Loxapine is combined with Phenprocoumon.]
[A08AA01, phentermine, Loxapine may decrease the stimulatory activities of Phentermine.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Loxapine.]
[C08CX01, mibefradil, The serum concentration of Mibefradil can be increased when it is combined with Loxapine.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Loxapine is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Loxapine is combined with Pindolol.]
[J05AE01, saquinavir, The serum concentration of Saquinavir can be increased when it is combined with Loxapine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Pipotiazine.]
[A02BX03, pirenzepine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Loxapine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Loxapine is combined with Piritramide.]
[N02CX01, pizotyline, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Loxapine is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Loxapine is combined with Alosetron.]
[S03AA03, polymyxin B, Loxapine may increase the neurotoxic activities of Polymyxin B.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Loxapine is combined with Prazepam.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Prilocaine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Loxapine is combined with Primidone.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Loxapine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Loxapine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Loxapine.]
[N05AA03, promazine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Loxapine is combined with Propanidid.]
[A03AB05, propantheline, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[R06AX26, fexofenadine, The serum concentration of Fexofenadine can be increased when it is combined with Loxapine.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Loxapine is combined with Periciazine.]
[N05CM06, propiomazine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Loxapine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Loxapine is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Loxapine is combined with Dextropropoxyphene.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Loxapine.]
[R03DC03, montelukast, The therapeutic efficacy of Montelukast can be decreased when used in combination with Loxapine.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Loxapine.]
[R01BA02, pseudoephedrine, Loxapine may decrease the stimulatory activities of Pseudoephedrine.]
[N05AX12, aripiprazole, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Loxapine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Loxapine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Loxapine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Loxapine is combined with Mepyramine.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Loxapine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Loxapine is combined with Quinine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Loxapine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Loxapine is combined with Oxitriptan.]
[S01FA02, scopolamine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Loxapine is combined with Secobarbital.]
[N04BD01, selegiline, The therapeutic efficacy of Selegiline can be decreased when used in combination with Loxapine.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Loxapine.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Loxapine.]
